Board members, management and employees acquire Hansa Medical shares and warrants

Hansa Medical AB (publ) today announced that board members, management and
employees have acquired shares and warrants in the company.
Hansa Medical’s CEO Göran Arvidson has acquired 30,000 shares and 150,000
warrants. Following the acquisition, Göran Arvidson’s total holding in Hansa
Medical amounts to 33,000 shares and 150,000 warrants.

The chairman of the board, Birgit Stattin Norinder, has acquired 6,000 shares.
Following the acquisition, Birgit Stattin Norinder’s total shareholding in the
company amounts to 29,205 shares.

Board member Per-Olof Wallström has acquired 6,000 shares. Following the
acquisition, Per-Olof Wallström’s total shareholding in the company amounts to
23,000 shares.

A total of 296,000 warrants were acquired by the company's employees, including
the CEO,  under the warrant program that Hansa Medical's Annual General Meeting
adopted on June 2, 2015.

About Hansa Medical’s share warrant program
Each warrant entitles the holder to subscribe for one new share in Hansa
Medical. Subscription for shares in accordance with the terms of the warrants
may take place during the period from June 15, 2018, and June 15, 2019. The
warrants are sold to the company's employees on market terms at a price
established on the basis of an estimated market value of the warrants using the
Black & Scholes model calculated by an independent valuation institute. The
value has been set at SEK 8.40 per option based on a share price of SEK 36,04.

The information in this press release is disclosed pursuant to the Securities
Markets Act or the Financial Instruments Trading Act. The information was
released for public disclosure on June 10, 2015, at 08.30 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO and CFO
Mobile: 46 70-390 85 30
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused
on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading
enzyme in clinical development, with potential use in transplantation and rare
autoimmune diseases. Other projects include HBP (a market introduced diagnostic
marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in
pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's
share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB
as Certified Adviser.